Certara, Inc. (NASDAQ:CERT) Receives $15.92 Consensus Target Price from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have received an average rating of “Hold” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $15.92.

CERT has been the topic of a number of research reports. Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Barclays lowered their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.39% of the company’s stock.

Hedge Funds Weigh In On Certara

Several institutional investors have recently bought and sold shares of the business. Blue Trust Inc. grew its holdings in shares of Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after purchasing an additional 2,076 shares during the last quarter. KBC Group NV grew its holdings in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after acquiring an additional 1,584 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Certara in the 2nd quarter valued at about $152,000. Algert Global LLC bought a new position in shares of Certara in the second quarter worth about $156,000. Finally, MQS Management LLC acquired a new position in shares of Certara during the second quarter worth approximately $162,000. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

NASDAQ CERT opened at $10.66 on Tuesday. The company’s fifty day moving average is $10.73 and its two-hundred day moving average is $12.13. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -53.30, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the business earned $0.06 earnings per share. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. Equities research analysts forecast that Certara will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.